Frontlight ResearchEarly access
CompletedPhase 3
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
Key facts
- Who runs it
- Epion Therapeutics
- Where
- Brookline, Charlottesville, Cincinnati, East Syracuse, Hoffman Estates, Houston, Miami, Philadelphia, Pittsburgh, Portland, Rowland Heights, San Francisco, and St Louis, United StatesSee the 13 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 396 people enrolled
- Started
- 30 Oct 2023
- Ended
- 12 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
- Placebo and sham treatment
- Record updated
- 25 June 2026
Who can take part
- Age
- 8 years to 45 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Diagnosis of keratoconus
Who cannot take part
- Contraindications or hypersensitivities to any required study medications
- Certain concomitant ocular conditions
- Non-keratoconic ectatic disease
- Minimal corneal thickness < 350 microns
- Pregnancy or breastfeeding
Where in United States
- Boston VisionBrookline, United States
- University of VirginiaCharlottesville, United States
- Cincinnati Eye InstituteCincinnati, United States
- The Eye Doctors at CNY Eye CareEast Syracuse, United States
- Chicago Cornea ConsultantsHoffman Estates, United States
- Baylor College of MedicineHouston, United States
- Center for Excellence in Eye CareMiami, United States
- Wills Eye HospitalPhiladelphia, United States
- UPMC Vision InstitutePittsburgh, United States
- Devers Eye InstitutePortland, United States
- Nvision Eye Centers Rowland HeightsRowland Heights, United States
- Goodman Eye CenterSan Francisco, United States
- Ophthalmology AssociatesSt Louis, United States
About the trial
What the trial wants to find out
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
The 2 groups in the trial
- Active TreatmentTreatment being tested
Epithelium-on corneal cross-linking
Treatment: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
- Control TreatmentPlacebo, for comparison
Placebo and sham for epithelium-on corneal cross-linking
Treatment: Placebo and sham treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus (APRICITY-A)
- Record updated
- 25 June 2026